FOLFOX for Colorectal Cancer: 108 Real Stories

108 stories match colorectal cancer and FOLFOX. 99 of them mention surgery.

Laura, who was diagnosed with Stage III Colorectal AdenocarcinomaColorectal Cancer

Stage III Colorectal Adenocarcinoma: Laura's Patient Story

Patient Info: Laura | Stage III

Laura completed about 6 months of chemotherapy after partial colectomy and returned to part-time work while continuing to manage fatigue.

Our Cancer Stories
OutcomeNot reported
Gina, who was diagnosed with Stage III Colorectal CancerColorectal Cancer

Stage III Colorectal Cancer: Gina's Patient Story

Patient Info: Gina | Stage III

The cancer returned in March near the original area. Gina completed radiation in August and was awaiting scans, with FOLFOX planned for November 2024.

Our Cancer Stories
OutcomeSetback / Progression
A patient, who was diagnosed with Stage IV Colorectal AdenocarcinomaColorectal Cancer

32-year-old woman with Stage IV rectal cancer, liver and lung metastases, targeted chemotherapy, surgery, ablation, radiation, and ongoing chemotherapy

Patient Info: Anonymized, Female, Under 40 | Stage IV

Biomarkers: KRAS wild-type; NRAS wild-type; BRAF wild-type

Metastatic Site: Liver | Lung | Presacral/perirectal lymph nodes

As of the story endpoint around December 2020, she was 5 years into treatment for Stage IV rectal cancer after multiple systemic regimens, bowel/liver/lung surgery, liver recurrence treatment, ablation, lung surgery, TOMO radiation, and ongoing chemotherapy.

Cancer361 (中文)
OutcomeCare Ongoing
A patient, who was diagnosed with Stage IV Colorectal AdenocarcinomaColorectal Cancer

A young man with metastatic rectal cancer and inherited BRCA1 and MLH1 mutations

Patient Info: Anonymized, Male, Under 40 | Stage IV

Biomarkers: Germline BRCA1 c.4065_4068delTCAA and MLH1 c.232G>T mutations; tumor microsatellite instability-high; loss of MLH1 and PMS2 expression; elevated tumor mutational burden; loss of heterozygosity of wild-type MLH1.

Metastatic Site: liver

The rectal and liver tumors showed a partial response, no viable carcinoma was found in the resected liver lesions, and maintenance nivolumab continued without evidence of growth or recurrence.

PubMed Central
OutcomeResponding Well
Barbara, who was diagnosed with Colorectal CancerColorectal Cancer

Colorectal Cancer: Barbara's Survivor Story

Patient Info: Barbara, Female, 40s

As of October 2021, Barbara described life after completed colon-cancer treatment, including survivorship, parenting, and a stronger perspective; recurrence was not described in this edited video.

The Patient Story
OutcomeSurvivorship / Completed Treatment
A patient, who was diagnosed with Stage IV Colorectal CancerColorectal Cancer

A Severe Delayed Immune Reaction After Treatment for Metastatic Colon Cancer

Patient Info: Anonymized, Male, 70+ | Stage IV

Metastatic Site: liver

He recovered from repeated episodes of severe cytokine release syndrome after prolonged corticosteroids, completed adjuvant FOLFOX and CV301 without nivolumab, and had no further CRS episodes.

PubMed Central
OutcomeCare Ongoing
A patient, who was diagnosed with Stage IV Colorectal CancerColorectal Cancer

Severe immune thrombocytopenia during treatment for metastatic colon cancer

Patient Info: Anonymized, Female, 50s | Stage IV

Biomarkers: KRAS-mutated; microsatellite stable; BRAF-wild type.

Metastatic Site: bilateral ovaries; pelvis; peritoneum; mesenteric…

After multiple metastatic recurrences and treatment changes, she died from progressive colon cancer; oxaliplatin had been permanently stopped after antibody-confirmed immune thrombocytopenia.

PubMed Central
OutcomeIn Memory
Lee, who was diagnosed with Stage IV Colorectal CancerColorectal Cancer

Stage IV Colorectal Cancer: Lee's Survivor Story

Patient Info: Lee Jones, Male, 50s | Stage IV

Metastatic Site: Liver

As of February 2021, Lee reported no evidence of colon cancer since 2011 after treatment for Stage IV colon cancer with liver metastases, recurrence, chemotherapy, colon surgery, and liver surgery.

The Patient Story
OutcomeCancer-Free / NED
Kyle, who was diagnosed with Stage IV Colorectal AdenocarcinomaColorectal Cancer

Stage IV Colorectal Adenocarcinoma: Kyle's Survivor Story

Patient Info: Kyle, Under 40 | Stage IV

Kyle was 19 months NED and off treatment after Stage IV colon adenocarcinoma, following about 30 months of chemotherapy and targeted therapy.

Our Cancer Stories
OutcomeCancer-Free / NED
A patient, who was diagnosed with Stage IV Colorectal AdenocarcinomaColorectal Cancer

Metastatic Right-Sided Colon Cancer With an NRG1 Fusion

Patient Info: Anonymized, Male, 60s | Stage IV

Biomarkers: KRAS mutation; POMK-NRG1 fusion

Metastatic Site: liver|lungs

He had persistent metastatic disease after 16 months of afatinib and entered a phase I trial in January 2020.

PubMed Central
OutcomeCare Ongoing
Maria, who was diagnosed with Stage IV Colorectal CancerColorectal Cancer

Stage IV Colorectal Cancer: Maria's Patient Story

Patient Info: Maria | Stage IV

Metastatic Site: lungs

After colorectal cancer spread to the lungs, completed 6 months of chemotherapy and is being monitored with CT scans every 3 months.

Our Cancer Stories
OutcomeLiving With Cancer
Amanda, who was diagnosed with Stage IV Colorectal AdenocarcinomaColorectal Cancer

Stage IV Colorectal Adenocarcinoma: Amanda's Patient Story

Patient Info: Amanda, Under 40 | Stage IV

She remains on ongoing treatment for Stage IV disease and describes the cancer as pretty stable while maintaining a good quality of life.

Our Cancer Stories
OutcomeStable Disease
A patient, who was diagnosed with Stage IV Colorectal AdenocarcinomaColorectal Cancer

Treatment-Related Inflammation Mimicked Metastatic Colon Cancer Recurrence

Patient Info: Anonymized, Male, 50s | Stage IV

Biomarkers: KRAS mutation

Metastatic Site: liver|peritoneum

Biopsy showed that new lymph-node, liver, and spleen findings were a treatment-related sarcoid-like reaction rather than recurrence, and 18 months of surveillance found no evidence of cancer.

PubMed Central
OutcomeCancer-Free / NED
Barbara, who was diagnosed with Stage III Colorectal CancerColorectal Cancer

Colon Cancer Stories: Barbara Majeski

Patient Info: Barbara Majeski, Female, 40s | Stage III

As of May 2020, Barbara was approaching the 5-year mark after Stage III colon cancer, with blood tests every 6 months and annual scans reported as good/clear.

The Patient Story
OutcomeCancer-Free / NED
A patient, who was diagnosed with Stage IV Colorectal AdenocarcinomaColorectal Cancer

An unusual paratesticular metastasis from colon cancer

Patient Info: Anonymized, Male, 50s | Stage IV

Biomarkers: CK20-positive; CDX2-positive; CK7-negative.

Metastatic Site: lungs; right paratesticular soft tissue

He recovered well after removal of the paratesticular metastasis and continued treatment for metastatic colon cancer with his oncology team.

PubMed Central
OutcomeCare Ongoing
Mary, who was diagnosed with Colorectal CancerColorectal Cancer

Colorectal Cancer: Mary's Patient Story

Patient Info: Mary

Within 12 months of the initial treatment course, further tumors were found during follow-up, including one in the liver.

Our Cancer Stories
OutcomeNot reported
A patient, who was diagnosed with Stage IV Colorectal AdenocarcinomaColorectal Cancer

Metastatic Colon Cancer With KRAS, NRAS, and BRAF Mutations

Patient Info: Anonymized, Male, 60s | Stage IV

Biomarkers: KRAS exon 3 ; NRAS exon 2 ; BRAF exon 10 ; PIK3CA exon 2 .

Metastatic Site: liver

The liver metastases progressed despite FOLFOX and bevacizumab, and he died within one year of the initial diagnosis.

PubMed Central
OutcomeIn Memory
A patient, who was diagnosed with Colorectal AdenocarcinomaColorectal Cancer

Colon Cancer and a Separate Liposarcoma Recurring at the Same Time

Patient Info: Anonymized, Male, 60s | Stage Metastatic/Advanced

Metastatic Site: liver|pelvic lymph node

Follow-up imaging showed no evidence of colon cancer after FOLFIRI produced a complete response in the liver and pelvic lymph node. He remained without evidence of disease 1.7 years after recurrence.

PubMed Central
OutcomeCancer-Free / NED